Michael Shah
analystMale0.0Global Dominance: 0.00%
Michael Shah is an industry analyst at Bloomberg Intelligence, focusing on the pharmaceutical sector. He has warned investors about the potential volatility in stock prices due to the influx of clinical trial results for obesity treatments in the coming months, highlighting the competitive landscape in this lucrative market.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Michael Shah, senior analyst at Bloomberg Intelligence, believes that this could start to resolve itself in time.
How weight-loss injections are making obesity a wealth issueBBC·
United Kingdom· 2025-09-29
United Kingdom· 2025-09-29
Local Sheriff Michael Shah stated that 11 injuries is too many, but thankfully there are no more.
11 פצועים מדקירות בחנות וולמארט במישיגן, חשוד נעצרידיעות אחרונות (Yedioth Ahronoth / ynet)·
Israel· 2025-07-27
Israel· 2025-07-27
Michael Shah, an industry analyst at Bloomberg Intelligence, warns about potential stock volatility.
¿Quién será el nuevo Ozempic? El mercado acelera la búsqueda de la siguiente revolución en la lucha contra la obesidad | Mercados FinancierosEl País·
Spain· 2025-02-10
Spain· 2025-02-10
